Date: 2015-05-06
Type of information: Nomination
Compound:
Company: Pfizer (USA - NY)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 6, 2015, Pfizer announced two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Pfizer’s Cambridge and Boston, Massachusetts locations. Dr. Ehlers will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwide Research & Development. In addition, John Lin, M.D., Ph.D., has been selected as Senior Vice President and Chief Scientific Officer of Rinat. Dr. Lin will report directly to Robert T. Abraham, Ph.D., Group Senior Vice President for Oncology-Rinat Research & Development. Dr. Michael D. Ehlers to Lead BioTherapeutics R&D: In his expanded role as Head of BioTherapeutics Research & Development, Dr. Ehlers will continue to be Chief Scientific Officer of Pfizer’s Neuroscience and Pain Research Unit and he will oversee the entire BioTherapeutics Research & Development organization. In connection with this appointment, the Inflammation and Immunology Research Unit will move to Pfizer’s PharmaTherapeutics Research & Development organization. Dr. Ehlers will be based in Cambridge, Massachusetts. Prior to joining Pfizer in 2010, Dr. Ehlers spent 12 years as the George Barth Geller Professor of Neurobiology and as a Howard Hughes Medical Institute Investigator at Duke University. He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. Dr. Ehlers is the recipient of numerous awards, including the 2013 Thudichum Medal from the Biochemical Society in the U.K., 2003 Eppendorf & Science Prize in Neurobiology, the 2007 John J. Abel Award in Pharmacology, the 2007 Society for Neuroscience Young Investigator Award, and the 2009 National Alliance for Schizophrenia and Depression Distinguished Investigator Award. Dr. Ehlers has authored more than 90 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry, and Molecular and Cellular Neuroscience, and sat on advisory committees of the National Institutes of Health. Dr. Ehlers will succeed José-Carlos Gutiérrez-Ramos, Ph.D., who has decided to return to the biotech sector in the Cambridge area. Dr. John Lin to Lead Rinat, Pfizer’s biotechnology unit within the Worldwide Research & Development organization, located in South San Francisco, California. Dr. Lin joined Rinat in 2002 and continued in his role when the biotechnology company was acquired by Pfizer in 2006. Since 2011, he has served as Vice President of Experimental Medicine at Rinat with responsibility for overseeing immuno-oncology and discovery and validation biology efforts with particular expertise in cellular, molecular and in vivo neurobiology. Dr. Lin received his medical and doctoral degrees from National Taiwan University and Harvard University, respectively, and also completed a postdoctoral fellowship at Genentech Inc. He has authored 25 peer-reviewed journal articles and reviews, and serves on the Grant Review Committee for the Michael J. Fox Foundation for Parkinson’s Research. Dr. Lin is succeeding Dr. Jaume Pons who left Rinat earlier this year to become President and CEO of Alexo Therapeutics. Dr. Charles Mackay Joining Pfizer as Head of Inflammation and Immunology Research Unit. As previously announced, Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer’s Inflammation and Immunology Research Unit. Professor Mackay will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President of PharmaTherapeutics Research & Development, and will be based in Pfizer’s R&D hub in Cambridge. Professor Mackay will join Pfizer from Monash University in Australia, where he is a research fellow, and the Charles Perkins Center within the Faculty of Medicine at Sydney University, where he was Chair of Diabetes.
Financial terms:
Latest news:
